Ovum analyst sees analytics boost in Oracle CDA 2.0

Oracle's CDA 2.0, the clinical data analytics system upgrade unveiled earlier this month, represents a big improvement over its predecessor, says pharmaceutical technology analyst Ruchi Mallya of Ovum Health Care Life Sciences. It adds a layer of analytics to provide clinical research managers with operational and performance metrics across all trial programs, offering information to optimize existing and future trials.

Mallya questioned the analytics capabilities when version 1.0 launched in February. She perceived more of a data management focus.

But version 2.0 incorporates 360 pre-built and pre-sourced metrics for clinical operational and performance management. It lets users combine into one repository past and current trial data through direct import from the software giant's Siebel CTMS, clinical system and remote data capture system. It answers a shortcoming Mallya saw in version 1.0 regarding synergies between CDA and other transactional e-clinical systems.

Mallya writes in Ovum's Straight Talk Opinion bulletin that she'd like to see the next version provide more seamless sourcing of data from Oracle and non-Oracle e-clinical solutions.

- here's Mallya's Straight Talk column

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.